Artivion (AORT) Q1 2025: Stent Graft Revenue Jumps 19% as AMDS and Onyx Recovery Fuel Guidance Raise
Artivion delivered a resilient Q1, clearing a third of its tissue backlog while stent graft and Onyx heart valve growth outperformed expectations. The company raised its full-year outlook as supply normalization and clinical tailwinds drive sequential acceleration, with AMDS and Onyx positioned for double-digit expansion. Investors should monitor execution on the tissue recovery timeline and AMDS account onboarding pace as the business leans into high-value U.S. opportunities.
Summary
- Stent Graft Acceleration: 19% constant currency growth highlights outperformance in complex aortic solutions.
- AMDS and Onyx Tailwinds: Early U.S. AMDS launch and compelling Onyx clinical data underpin market share gains.
- Guidance Raised: Full-year outlook increased as tissue backlog clears and new product launches ramp through 2025.
Performance Analysis
Artivion posted 4% constant currency revenue growth in Q1, overcoming lingering headwinds from a previously disclosed cybersecurity incident that primarily affected its tissue business. The company’s stent graft segment delivered standout 19% growth, powered by demand for complex aortic solutions and the initial U.S. launch of AMDS, a humanitarian device exemption (HDE) product for aortic dissection. Onyx, the company’s mechanical heart valve, grew 11% as supply constraints eased and new clinical data reinforced its positioning for younger patients. BioGlue, a surgical adhesive, contributed 9% growth, while tissue processing revenue fell 23% due to backlog from the cyber event.
Geographically, Latin America and Asia Pacific posted double-digit gains, while North America declined as tissue headwinds persisted. Gross margin compressed slightly to 64.2%, reflecting lower high-margin tissue revenue and incremental AMDS launch investments. Adjusted EBITDA margin held steady, with disciplined expense management offsetting temporary cost pressure. Management’s ability to clear one-third of the tissue backlog ahead of schedule and restore Onyx supply was a key operational highlight, supporting improved visibility for the remainder of the year.
- Stent Graft Outperformance: 19% growth reflects both U.S. AMDS launch momentum and European cross-selling leverage.
- Onyx Supply Recovery: Double-digit growth achieved as manufacturing normalized and demand outstripped supply.
- Tissue Backlog Progress: One-third of backlog cleared, with full recovery targeted by Q3, supporting guidance confidence.
With sequential improvement expected across segments, Artivion raised its full-year revenue guidance and expects margin expansion as product mix shifts toward higher-value offerings.
Executive Commentary
"We're extremely pleased with our first quarter performance, which exceeded our initial expectations, despite the timing impact of the cybersecurity incident. I'd like to take a moment to recognize our team's outstanding work in ramping up Onyx Apply, which has now returned to normal levels and in clearing approximately one-third of our tissue processing backlog ahead of schedule. Also, the U.S. sales force is off to a great start on the AMDS launch."
Pat Mackin, CEO
"We made some great progress in Q1 on clearing our tissue supply backlog, catching up on our ONIX supply, and building our AMDS pipeline, and have greater conviction on our ability to deliver our full-year guidance."
Lance Barry, CFO
Strategic Positioning
1. AMDS Launch and U.S. Market Entry
AMDS, a device for aortic dissection under HDE, is central to Artivion’s U.S. growth strategy. With 150 facilities actively seeking approval, the onboarding process—requiring IRB, value analysis committee, and surgeon training—is progressing faster than anticipated. Management cited a 100% success rate at targeted accounts and expects sequential sales growth through 2025, with a $150 million annual U.S. market opportunity in play.
2. Onyx Valve: Clinical Data and Share Gains
Onyx, a mechanical heart valve, benefits from new STS database data showing mortality benefits for patients under 60 versus bioprosthetic valves. This evidence opens a $100 million U.S. market expansion, reinforcing management’s conviction in double-digit growth and global market share gains, especially as supply constraints abate.
3. Tissue Processing: Backlog and Recovery
The tissue processing business, heavily impacted by the cyber incident, is on track for a full recovery by Q3. Management expects a return to mid-single-digit growth for the year, with backlog clearance driving sequential improvement and supporting overall margin recovery.
4. Nexus Pipeline and M&A Option
Nexus, an aortic arch stent graft system, delivered positive 30-day IDE trial results with a 63% reduction in major adverse events. This positions Artivion for a potential $150 million U.S. market entry in 2026, pending FDA approval and exercise of its $135 million acquisition option on Endospan, the product’s developer.
5. Global Expansion and Regulatory Leverage
Latin America and Asia Pacific expansion, driven by regulatory approvals and commercial footprint buildout, continues to deliver robust constant currency growth. Management sees these regions as ongoing growth engines as product portfolios broaden.
Key Considerations
Artivion’s Q1 demonstrated operational resilience and strategic progress, but the path forward depends on execution in several critical areas. The company’s ability to capitalize on new product launches, clear operational bottlenecks, and navigate regulatory timelines will shape its growth trajectory and margin profile.
Key Considerations:
- AMDS Account Onboarding Pace: The speed of IRB and value analysis approvals at U.S. hospitals will determine the slope of AMDS ramp and revenue contribution.
- Tissue Backlog Resolution: Timely clearance of the remaining tissue backlog is essential for restoring high-margin revenue and supporting margin expansion.
- Clinical Adoption of Onyx: Leveraging recent mortality data to drive conversion from bioprosthetic to mechanical valves is a key commercial lever.
- M&A Option on Nexus: Successful FDA approval and integration of Endospan’s Nexus device is a major future catalyst, with financing and execution risk to monitor.
- Expense Discipline: Managing SG&A and R&D investments amid new product launches will be critical to delivering targeted EBITDA leverage.
Risks
Execution risk remains elevated around tissue backlog clearance, AMDS onboarding speed, and supply normalization for Onyx. Regulatory delays for Nexus or AMDS PMA could shift the growth timeline. Currency volatility and incremental cyber or supply chain disruptions represent ongoing operational threats. The company’s leverage, while improving, still constrains flexibility ahead of potential M&A.
Forward Outlook
For Q2 2025, Artivion guided to:
- Reported revenue of $107.5 to $109.5 million (13% constant currency growth at midpoint)
For full-year 2025, management raised guidance:
- Constant currency revenue growth of 11% to 14%
- Reported revenue of $423 million to $435 million
- Adjusted EBITDA of $84 million to $91 million (18% to 28% YoY growth)
Management highlighted sequential acceleration in AMDS sales, full tissue backlog clearance by Q3, and margin expansion from product mix as drivers of second-half outperformance.
- AMDS and Onyx expected to drive above-market growth rates.
- Expense and FX headwinds remain manageable, with upside possible if current rates hold.
Takeaways
Artivion’s Q1 performance validates its recovery trajectory, with stent graft and Onyx momentum offsetting temporary tissue headwinds. The company’s raised guidance and confidence in sequential acceleration reflect both operational progress and strong clinical tailwinds.
- Product Mix Shift Drives Upside: Stent graft and Onyx outperformance, coupled with AMDS ramp, are set to lift both revenue and margin through 2025.
- Tissue Recovery Remains a Key Watchpoint: Timely backlog clearance is needed to unlock full-year margin and growth targets.
- Pipeline and M&A Catalysts on the Horizon: Nexus IDE progress and the Endospan acquisition option set up a potential new leg of growth in 2026.
Conclusion
Artivion’s operational recovery and portfolio momentum position it for sustained double-digit growth, with AMDS and Onyx at the center of its strategic focus. Investors should watch for execution on tissue normalization and account onboarding, as these will determine the pace and durability of margin expansion and top-line acceleration.
Industry Read-Through
Artivion’s Q1 underscores the resilience and growth opportunity in complex aortic and heart valve interventions, especially as clinical data shifts standard-of-care preferences. The rapid normalization from a cyber disruption highlights the operational risks medtech firms face as digital infrastructure becomes more critical. The AMDS HDE launch and Nexus IDE progress signal that regulatory innovation and clinical differentiation remain key levers for market expansion. Competitors in aortic, valve, and cardiac surgery segments should monitor both clinical trial readouts and the pace of U.S. hospital onboarding as leading indicators of share shifts and adoption curves.